Development and validation of a novel non‐invasive test for diagnosing fibrotic non‐alcoholic steatohepatitis in patients with biopsy‐proven non‐alcoholic fatty liver disease DOI
Feng Gao, Jiaofeng Huang, Kenneth I. Zheng

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2020, Volume and Issue: 35(10), P. 1804 - 1812

Published: April 4, 2020

There is an immediate need for non-invasive accurate tests diagnosing liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Previously, it has been suggested that MACK-3 (a formula combines homeostasis model assessment-insulin resistance serum aspartate aminotransferase and cytokeratin [CK]18-M30 levels) accurately identifies fibrotic NASH. Our aim was to assess the performance of develop a novel, algorithm NASH.Six hundred thirty-six adults biopsy-proven fatty disease (NAFLD) from two independent Asian cohorts were enrolled our study. Liver stiffness measurement (LSM) assessed by vibration-controlled transient elastography (Fibroscan). Fibrotic NASH defined as NAFLD activity score (NAS) ≥ 4 F 2 fibrosis.Metabolic syndrome (MetS), platelet count predictors On basis their regression coefficients, we developed novel nomogram showing good discriminatory ability (area under receiver operating characteristic curve [AUROC]: 0.79, 95% confidence interval [CI 0.75-0.83]) high negative predictive value (NPV: 94.7%) rule out In validation set, this had higher AUROC (0.81, 95%CI 0.74-0.87) than (AUROC: 0.75, 0.68-0.82; P < 0.05) NPV 93.2%. The sequential combination LSM data avoided biopsy 56.9% patients.Our (combining MACK-3, MetS) shows promising utility limits indeterminate results reduces number unnecessary biopsies.

Language: Английский

Complications, morbidity and mortality of nonalcoholic fatty liver disease DOI
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca

et al.

Metabolism, Journal Year: 2020, Volume and Issue: 111, P. 154170 - 154170

Published: Jan. 30, 2020

Language: Английский

Citations

443
NAFLD as a driver of chronic kidney disease DOI Open Access
Christopher D. Byrne, Giovanni Targher

Journal of Hepatology, Journal Year: 2020, Volume and Issue: 72(4), P. 785 - 801

Published: Feb. 12, 2020

Language: Английский

Citations

349
Association of metabolic dysfunction-associated fatty liver disease with kidney disease DOI
Ting-Yao Wang,

Rui-Fang Wang,

Zhi-Ying Bu

et al.

Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(4), P. 259 - 268

Published: Jan. 10, 2022

Language: Английский

Citations

151
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease DOI Open Access
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne

et al.

HepatoBiliary Surgery and Nutrition, Journal Year: 2023, Volume and Issue: 12(3), P. 386 - 403

Published: Feb. 24, 2023

With the rising global prevalence of fatty liver disease related to metabolic dysfunction, association this common condition with chronic kidney (CKD) has become increasingly evident. In 2020, more inclusive term dysfunction-associated (MAFLD) was proposed replace non-alcoholic (NAFLD). The observed between MAFLD and CKD our understanding that can be a consequence underlying dysfunction support notion individuals are at higher risk having developing compared those without MAFLD. However, date, there is no appropriate guidance on in Furthermore, been little attention paid link Nephrology community.Using Delphi-based approach, multidisciplinary panel 50 international experts from 26 countries reached consensus some open research questions regarding CKD.This statement provided epidemiology, mechanisms, management treatment CKD, as well relationship severity which establish framework for early prevention these two interconnected diseases.

Language: Английский

Citations

59
Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis DOI Creative Commons
Xuefeng Ma, Shousheng Liu, Jie Zhang

et al.

BMC Gastroenterology, Journal Year: 2020, Volume and Issue: 20(1)

Published: Jan. 14, 2020

Abstract Background ALT value is often used to reflect the hepatic inflammation and injury in NAFLD patients, but many studies proved that values were normal patients. The aim of this study was identify summarized proportion patients with overall Methods Electronic databases PubMed, EMBASE, Ovid, Cochrane Library searched for potential published from January 1, 2000 September 30, 2019. Studies have reported number or NASH abnormal included analyzed. Abstracts, reviews, case reports, letters excluded. Results A total 11 4084 assessing As results shown, 25% (95%CI: 20–31%) which calculated by random-effects model. 19% 13–27%). Subgroup analysis includes region, type, diagnostic method, group size conducted investigate resource heterogeneity value. Conclusions possess clinical manifestation. diagnosis remains need be further testified.

Language: Английский

Citations

119
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? DOI Creative Commons
Seong Hee Kang, Yuri Cho, Soung Won Jeong

et al.

Clinical and Molecular Hepatology, Journal Year: 2021, Volume and Issue: 27(2), P. 257 - 269

Published: March 22, 2021

There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes importance of metabolic risk factors in this disease. Recently, a consensus recommended “metabolic (dysfunction)-associated (MAFLD)” as more appropriate to describe diseases (FLD) associated dysfunction. During definition change from NAFLD MAFLD, subjects FLD abnormalities, together other etiologies such alcohol, virus, or medication who have been excluded criteria, were added MAFLD while but without abnormality, included criteria. This means that there an emphasis on dysfunction may underestimate prognostic value hepatic steatosis itself, whereas criteria might better identify are at higher cardiovascular outcomes. However, non-metabolic missed diagnosis, their potential can be cause future diseases. Although huge controversies remain, review focused summarizing recent studies compared clinical characteristics between MAFLD.

Language: Английский

Citations

77
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications DOI Open Access
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(21), P. 13320 - 13320

Published: Nov. 1, 2022

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic worldwide, affecting up to ~30% adult populations. NAFLD defines a spectrum progressive conditions ranging from simple steatosis nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma, which often occur in close bidirectional associations with metabolic disorders. Chronic kidney (CKD) is characterized by anatomic and/or functional renal damage, ultimately resulting reduced glomerular filtration rate. The physiological axis linking kidneys passes unnoticed until clinically significant portal hypertension, as major complication becomes apparent form ascites, refractory or hepatorenal syndrome. However, extensive evidence accumulated since 2008 indicates that noncirrhotic associated higher risk incident CKD, independent obesity, type 2 diabetes, other factors. In addition, subclinical hypertension been demonstrated NAFLD, potential adverse impact on vasoregulation. mechanisms underlying this association remain unexplored substantial extent. With background, review we discuss current showing strong between putative biological underpinning association. We also depth pathogenic role reflex, may be triggered poorly investigated but promising research topic. Finally, address emerging pharmacotherapies for beneficially affect developing CKD individuals NAFLD.

Language: Английский

Citations

40
MAFLD as part of systemic metabolic dysregulation DOI
Jing Zhao, Lu Liu,

Yingying Cao

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 834 - 847

Published: April 9, 2024

Language: Английский

Citations

15
Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China DOI Creative Commons
Jingfeng Chen,

Zhuo-Qing Wu,

H. Liu

et al.

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(10), P. 1346 - 1357

Published: March 14, 2024

Within the normal range, elevated alanine aminotransferase (ALT) levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease (MAFLD).

Language: Английский

Citations

12
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review DOI Open Access
Amedeo Lonardo

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(2)

Published: April 7, 2024

Chronic kidney disease (CKD) and nonalcoholic fatty liver (NAFLD), metabolic dysfunction-associated (MAFLD) steatotic (MASLD) account for substantial financial burden worldwide. These alarming features call enhanced efforts to prevent manage the development progression of CKD. Accumulating evidence supporting a causal role NAFLD/MAFLD/MASLD-in CKD opens new horizons achieve this aim. Recent epidemiological studies meta-analyses exploring association NAFLD/MAFLD/MASLD with characteristics associated odds incident are discussed. The involved pathomechanisms, including common soil hypothesis, genetics, gut dysbiosis, portal hypertension, examined in detail. Finally, lifestyle changes (diet physical exercise), direct manipulation microbiota, drug approaches involving statins, renin-angiotensin-aldosterone system inhibitors, GLP-1 Receptor Agonists, Sodium-glucose cotransporter-2, pemafibrate, vonafexor within context prevention management among those NAFLD/MAFLD/MASLD. evolving nomenclature may generate confusion practicing clinicians investigators. However, comparative investigating pros contra different nomenclatures identify most useful definitions strategies identify, prevent, halt onset

Language: Английский

Citations

9